Monaco Asset Management SAM Invests $402,000 in Vaxart, Inc. (NASDAQ:VXRT)

Monaco Asset Management SAM acquired a new stake in Vaxart, Inc. (NASDAQ:VXRT - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 601,700 shares of the biotechnology company's stock, valued at approximately $402,000. Monaco Asset Management SAM owned approximately 0.34% of Vaxart at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in VXRT. RA Capital Management L.P. bought a new stake in Vaxart in the first quarter worth about $20,000,000. Vanguard Group Inc. raised its holdings in shares of Vaxart by 19.9% in the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company's stock worth $10,984,000 after purchasing an additional 1,404,391 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new stake in Vaxart during the second quarter valued at approximately $65,000. Tidal Investments LLC bought a new stake in Vaxart during the first quarter worth approximately $56,000. Finally, Kingswood Wealth Advisors LLC acquired a new position in Vaxart in the first quarter worth approximately $32,000. Institutional investors and hedge funds own 18.05% of the company's stock.

Analysts Set New Price Targets

Separately, Oppenheimer initiated coverage on Vaxart in a research report on Thursday, August 15th. They set an "outperform" rating and a $4.00 price objective for the company.

Vaxart Stock Performance

VXRT traded up $0.02 during trading on Tuesday, reaching $0.91. The company had a trading volume of 819,646 shares, compared to its average volume of 2,818,369. The firm's 50-day simple moving average is $0.73 and its 200 day simple moving average is $0.86. The company has a market cap of $161.87 million, a price-to-earnings ratio of -1.69 and a beta of 0.65. Vaxart, Inc. has a 12-month low of $0.52 and a 12-month high of $1.54.

Vaxart (NASDAQ:VXRT - Get Free Report) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Vaxart had a negative return on equity of 114.19% and a negative net margin of 543.21%. The firm had revenue of $6.40 million during the quarter, compared to analyst estimates of $65.70 million. During the same quarter in the previous year, the business earned ($0.16) earnings per share. On average, sell-side analysts expect that Vaxart, Inc. will post -0.47 EPS for the current year.

Vaxart Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.